Rogco LP Increases Stock Position in Stryker Corporation $SYK

Rogco LP increased its position in shares of Stryker Corporation (NYSE:SYK) by 26.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,331 shares of the medical technology company’s stock after buying an additional 276 shares during the period. Rogco LP’s holdings in Stryker were worth $527,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Mogy Joel R Investment Counsel Inc. lifted its stake in shares of Stryker by 3.4% in the first quarter. Mogy Joel R Investment Counsel Inc. now owns 98,216 shares of the medical technology company’s stock worth $36,561,000 after acquiring an additional 3,218 shares in the last quarter. Ferguson Wellman Capital Management Inc. increased its holdings in Stryker by 1.9% during the 1st quarter. Ferguson Wellman Capital Management Inc. now owns 174,871 shares of the medical technology company’s stock worth $65,096,000 after purchasing an additional 3,341 shares during the last quarter. Harbor Capital Advisors Inc. purchased a new position in shares of Stryker during the 1st quarter valued at approximately $1,840,000. Mar Vista Investment Partners LLC boosted its stake in shares of Stryker by 10.2% during the 1st quarter. Mar Vista Investment Partners LLC now owns 90,187 shares of the medical technology company’s stock valued at $33,572,000 after buying an additional 8,353 shares during the last quarter. Finally, United Services Automobile Association acquired a new stake in shares of Stryker during the first quarter worth approximately $2,857,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

Stryker Price Performance

NYSE SYK opened at $369.44 on Wednesday. Stryker Corporation has a 12 month low of $329.16 and a 12 month high of $406.19. The firm has a market capitalization of $141.24 billion, a PE ratio of 48.93, a P/E/G ratio of 2.67 and a beta of 0.93. The company’s 50 day simple moving average is $384.81 and its 200 day simple moving average is $379.11. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.06.

Stryker (NYSE:SYK) last released its earnings results on Thursday, July 31st. The medical technology company reported $3.13 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.07 by $0.06. The firm had revenue of $6.02 billion for the quarter, compared to analyst estimates of $5.92 billion. Stryker had a return on equity of 23.94% and a net margin of 12.25%.Stryker’s revenue was up 11.1% compared to the same quarter last year. During the same period in the previous year, the company earned $2.81 earnings per share. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. As a group, equities research analysts forecast that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be given a $0.84 dividend. The ex-dividend date is Tuesday, September 30th. This represents a $3.36 annualized dividend and a yield of 0.9%. Stryker’s payout ratio is 44.50%.

Insiders Place Their Bets

In other news, insider Viju Menon sold 500 shares of the firm’s stock in a transaction on Monday, August 25th. The stock was sold at an average price of $390.61, for a total transaction of $195,305.00. Following the completion of the sale, the insider directly owned 12,511 shares of the company’s stock, valued at $4,886,921.71. This trade represents a 3.84% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Ronda E. Stryker sold 200,000 shares of Stryker stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total value of $75,290,000.00. Following the completion of the transaction, the director owned 3,222,108 shares in the company, valued at $1,212,962,556.60. The trade was a 5.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.20% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of research analysts have commented on the stock. Truist Financial set a $415.00 price objective on shares of Stryker and gave the company a “hold” rating in a research note on Monday, August 4th. Wall Street Zen cut shares of Stryker from a “buy” rating to a “hold” rating in a research report on Friday, September 26th. Rothschild & Co Redburn assumed coverage on Stryker in a report on Thursday, September 18th. They issued a “neutral” rating and a $420.00 price target for the company. BTIG Research restated a “buy” rating on shares of Stryker in a research note on Monday, July 14th. Finally, Rothschild Redb raised shares of Stryker to a “hold” rating in a report on Thursday, September 18th. Fourteen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $430.33.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.